Transplantation of Mitochondria isolated from iPSC-MSCs mitigates doxorubicin-induced cardiomyopathy by inhibiting cardiomyocyte senescence.

Qi Yang, Shibing Zhao, Junxiu Zhao, Ying Shen, Yimei Hong, Jie Qiu, Ziqi Li, Fang Lin, Kexin Ma, Bei Hu, Yuelin Zhang, Xiaoting Liang

Department of Emergency Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.Department of Emergency Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China. · pubmed

Paper

Abstract

Mitochondrial dysfunction plays an important role in the development of doxorubicin-induced cardiomyopathy (DIC). Mitochondrial transplantation (MT) exerts beneficial effects on multiple cardiovascular diseases.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that mitochondrial transplantation from iPSC-MSCs can reduce cardiomyocyte senescence and mitigate doxorubicin-induced cardiomyopathy. This research is relevant as it addresses mitochondrial dysfunction, a key factor in aging and age-related diseases, potentially offering insights into interventions that could impact longevity.

Author of this paper? Send a correction.